Source: Virtual Congress 2021 – Cystic fibrosis



Rating:

Share or cite this content

Citations should be made in the following way:
C. Schwarz (Potsdam, Germany), C. Procaccianti (Parma, Italy), D. Belmans (Kontich, Belgium), B. Mignot (Kontich, Belgium), N. Schwenck (Starnberg, Germany), X. Murgia (Zamudio, Spain), F. Bianco (Parma, Italy), C. Procaccianti (MILAN, Italy). Functional respiratory imaging assessment of the aerosol deposition of inhaled levofloxacin in cystic fibrosis lungs. 2192

Member's Comments

No comment yet.

Related content which might interest you: Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis Source: Eur Respir J 2002; 20: 122-126 Year: 2002 The assesment of aerosol solution lung deposition in cystic fibrosis patients Source: Eur Respir J 2004; 24: Suppl. 48, 584s Year: 2004 Reduced uptake of inhaled carbon in airway macrophages from children with cystic fibrosis Source: International Congress 2018 – Latest developments in cystic fibrosis Year: 2018 Efficacy of peripheral deposition of inhaled rhDNase in CF patients during a respiratory tract exacerbation Source: Annual Congress 2010 - Cystic fibrosis: clinical and laboratory studies Year: 2010 Deposition of inhaled nanoparticles, airflow obstruction and emphysema Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Urinary excretion reflects lung deposition of aminoglycoside aerosols in cystic fibrosis Source: Eur Respir J 2001; 18: 316-322 Year: 2001 Evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections Year: 2016 Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: Evaluation of exacerbations and lung function Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016 Long-term administration of aerosolised tobramycin in patients with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 619s Year: 2005 Inhalation therapy in cystic fibrosis Source: School Course 2013 - Cystic Fibrosis Year: 2013 Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis Source: Eur Respir J , 49 (3) 1600987; DOI: 10.1183/13993003.00987-2016 Year: 2017 Free-breathing MRI for monitoring ventilation changes following antibiotic treatment of pulmonary exacerbations in paediatric cystic fibrosis Source: Eur Respir J, 57 (4) 2003104; 10.1183/13993003.03104-2020 Year: 2021 Effect of high dose tobramicin (TOBI®) inhalation on respiratory values in cystic fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 503s Year: 2003 Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis Source: Eur Respir J 2003 Dec 01;22(6):972-979 Year: 2003 Early detection of pulmonary exacerbations in children with cystic fibrosis by electronic home monitoring of symptoms and lung function Source: International Congress 2016 – Cystic fibrosis: monitoring and management Year: 2016 Health status impact of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis Year: 2011 Changes in lung gas mixing after physiotherapy in adults with cystic fibrosis Source: Annual Congress 2007 - Critical care and airways clearance Year: 2007 RhDNase after airway clearance therapy improves peripheral airway patency in children with cystic fibrosis Source: Annual Congress 2006 - Cystic fibrosis lung disease: molecules images and drugs Year: 2006